Sign In
Buy SYRE
$98.33
-3.17 (-3.12%)
At Close: Jul 31, 2026
Spyre Therapeutics' CEO Sells 15,000 Shares
09:17am, Sunday, 11'th Jan 2026
The CEO sold 15,000 shares for over $460,000 on Jan. 2, 2026. The sale represented 2.2% of Cameron Turtle's holdings His transactions reduced his direct ownership to 671,907 shares.
Spyre Therapeutics Announces Grants of Inducement Awards
04:05pm, Thursday, 08'th Jan 2026
WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies a
Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock
04:52am, Thursday, 08'th Jan 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the firm's stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $
Spyre Therapeutics: Validated Targets, Optimized Delivery
04:36am, Thursday, 01'st Jan 2026
Spyre Therapeutics offers a de-risked clinical pipeline and a robust cash runway extending into H2 2028, mitigating near-term financing risk. SYRE's portfolio targets validated mechanisms—alpha-4 be
Spyre Therapeutics Announces Grants of Inducement Awards
04:05pm, Friday, 05'th Dec 2025
WALTHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies a
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Intech Investment Management LLC
05:06am, Monday, 01'st Dec 2025
Intech Investment Management LLC raised its holdings in Spyre Therapeutics, Inc. (NASDAQ: SYRE) by 22.1% in the undefined quarter, according to its most recent 13F filing with the Securities and Excha
Spyre Therapeutics Announces Grants of Inducement Awards
04:05pm, Friday, 07'th Nov 2025
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies a
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 04'th Nov 2025
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or tw
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
04:01pm, Tuesday, 04'th Nov 2025
SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
08:00am, Friday, 24'th Oct 2025
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefin
WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody en
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
09:07pm, Monday, 13'th Oct 2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody en
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
04:01pm, Monday, 13'th Oct 2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody en
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
09:00am, Sunday, 05'th Oct 2025
WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and r
Intelligent Development Could Make Spyre Therapeutics Best In Show
10:34pm, Thursday, 18'th Sep 2025
Spyre Therapeutics has multiple potential best-in-class antibodies in its pipeline to treat ulcerative colitis, a trial design that tests combinations of these antibodies, and cash to run that trial.
